Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Tdcp vaccine in participants aged 6 years and older
CTR20244441Phase 3Active
- Sponsor
- CanSino Biologics Inc.
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed in pertussis, diphtheria, Tetanus, sponsored by CanSino Biologics Inc.. Started Feb 2025; status: active.
02
Drugs
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on CTR20244441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244441.